XLRN - Acceleron's sotatercept shows potential to treat pulmonary arterial hypertension in mid-stage Pulsar trial

Acceleron Pharma (XLRN) announces interim results from the open-label extension of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension ((PAH)). The investigators observed maintained or enhanced responses with sotatercept treatment in multiple study endpoints evaluated at week 48, including six-minute walk distance (6MWD) and World Health Organization functional class.Patients treated with sotatercept in all cohorts also experienced reductions in levels of amino-terminal brain natriuretic propeptide (NT-proBNP), a hormone secreted by cardiac muscle cells in response to stretching caused by increased blood volume in the heart.Sotatercept was generally well tolerated. Adverse events observed in the study were generally consistent with previously published data. "This suggests that sotatercept is acting in a manner distinct from other agents, possibly by balancing pro- and anti-proliferative signaling in pathways known to be relevant in PAH biology,” said said Dr. David Badesch, Professor of Medicine and Clinical Director of the Pulmonary Hypertension

For further details see:

Acceleron's sotatercept shows potential to treat pulmonary arterial hypertension in mid-stage Pulsar trial